Jan Siehl
Impact in
-
- Viral-associated cancers and disorders
- Pathology and Forensic Medicine top 10%
- Lymphoma Diagnosis and Treatment
Papers in
- Oncology 14
- Viral-associated cancers and disorders 9
- Cancer Treatment and Pharmacology 2
-
- Renal and related cancers 4
- Ubiquitin and proteasome pathways 2
- Co-authors
- Eckhard Thiel (9 shared papers)Ulrich Keilholz (15 shared papers)Hans D. Menssen (4 shared papers)Marcus Hentrich (8 shared papers)Alexander Schmittel (11 shared papers)Christoph Wyen (8 shared papers)Markus Müller (3 shared papers)Nikolaos E. Bechrakis (3 shared papers)
- Journals
- Journal of Clinical Oncology (8 papers)Annals of Hematology (3 papers)European Journal of Cancer (2 papers)Hematological Oncology (1 paper)British Journal of Haematology (1 paper)
- Partner nations
- GermanyUnited StatesEstonia
In The Last Decade
Jan Siehl
26 papers receiving 398 citations
Peers
Comparison fields: 5 of 45
- Oncology 191
- Pathology and Forensic Medicine 104
- Ophthalmology 48
- Hematology 59
- Genetics 38
Countries citing papers authored by Jan Siehl
This map shows the geographic impact of Jan Siehl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Siehl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Siehl more than expected).
Fields of papers citing papers by Jan Siehl
This network shows the impact of papers produced by Jan Siehl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Siehl. The network helps show where Jan Siehl may publish in the future.
Co-authors
The 25 scholars most cited alongside Jan Siehl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2012 | 77 | |
| 2 | 2007 | 37 | |
| 3 | 2004 | 35 | |
| 4 | 2005 | 32 | |
| 5 | 2002 | 25 | |
| 6 | 2003 | 25 | |
| 7 | 2011 | 24 | |
| 8 | 2009 | 23 | |
| 9 | 2018 | 23 | |
| 10 | 2005 | 20 | |
| 11 | 2014 | 20 | |
| 12 | 2004 | 15 | |
| 13 | 2017 | 11 | |
| 14 | 2006 | 11 | |
| 15 | 2000 | 7 | |
| 16 | 2013 | 6 | |
| 17 | Phase II trial of carboplatin, paclitaxel plus vinorelbine in non-small cell lung cancer patients. | 2005 | 4 |
| 18 | 2001 | 3 | |
| 19 | 2004 | 3 | |
| 20 | 2011 | 2 |
About Jan Siehl
Jan Siehl is a scholar working on Oncology, Molecular Biology, Pathology and Forensic Medicine, Hematology and Pulmonary and Respiratory Medicine, having authored 29 papers that have together received 409 indexed citations. Recurring topics across this work include Viral-associated cancers and disorders (9 papers), Lymphoma Diagnosis and Treatment (8 papers), Sarcoma Diagnosis and Treatment (4 papers), Renal and related cancers (4 papers), Multiple Myeloma Research and Treatments (4 papers), Ocular Oncology and Treatments (4 papers), Ubiquitin and proteasome pathways (2 papers) and Cancer Treatment and Pharmacology (2 papers). The work is most often cited by research in Oncology (191 citations), Pathology and Forensic Medicine (104 citations), Ophthalmology (48 citations), Hematology (59 citations) and Genetics (38 citations). Jan Siehl has collaborated with scholars based in Germany, United States and Estonia. Frequent co-authors include Eckhard Thiel, Ulrich Keilholz, Hans D. Menssen, Marcus Hentrich, Alexander Schmittel, Christoph Wyen, Markus Müller, Nikolaos E. Bechrakis, R. Schuster and Timo Wolf. Their work appears in journals such as Journal of Clinical Oncology, Annals of Hematology, European Journal of Cancer, Hematological Oncology and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.